Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 7 results.
User Information
Export Records
  1. 1.   Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer
  2. Palmieri, D.; Halverson, D. O.; Ouatas, T.; Horak, C. E.; Salerno, M.; Johnson, J.; Figg, W. D.; Hollingshead, M.; Hursting, S.; Berrigan, D.; Steinberg, S. M.; Merino, M. J.; Steeg, P. S.
  3. Journal of the National Cancer Institute. 2005, MAY 4; 97(9): 632-642.
  1. 2.   Endogenous leukemia inhibitory factor attenuates endotoxin response
  2. Weber, M. A.; Schnyder-Candrian, S.; Schnyder, B.; Quesniaux, V.; Poli, V.; Stewart, C. L.; Ryffel, B.
  3. Laboratory Investigation. 2005, FEB; 85(2): 276-284.
  1. 3.   Ablation of TrkA function in the immune system causes B cell abnormalities
  2. Coppola, V.; Barrick, C. A.; Southon, E. A.; Celeste, A.; Wang, K.; Chen, B.; Haddad, E. B.; Yin, J.; Nussenzweig, A.; Subramaniaml, A.; Tessarollo, L.
  3. Development. 2004, OCT; 131(20): 5185-5195.
  1. 4.   Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells
  2. Hodge, D. R.; Xiao, W. H.; Wang, L. H.; Li, D. P.; Farrar, W. L.
  3. Cancer Biology & Therapy. 2004 3(2): 188-194.
  1. 5.   Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk
  2. Peters, U.; Hayes, R. B.; Chatterjee, N.; Shao, W.; Schoen, R. E.; Pinsky, P.; Hollis, B. W.; McGlynn, K. A.
  3. Cancer Epidemiology Biomarkers & Prevention. 2004 13(4): 546-552.
  1. 6.   Effects of organ-specific loss of insulin-like growth factor-I production on murine hematopoiesis
  2. Welniak, L. A.; Karas, M.; Yakar, S.; Anver, M. R.; Murphy, W. F.; LeRoith, D.
  3. Biology of Blood and Marrow Transplantation. 2004 10(1): 32-39.
  1. 7.   Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: A randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
  2. Smith, J. W.; Kurt, R. A.; Baher, A. G.; Denman, S.; Justice, L.; Doran, T.; Gilbert, T.; Alvord, W. G.; Urba, W. J.
  3. Journal of Immunotherapy. 2003 26(2): 130-138.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel